Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridioides difficile spore surface antigens are a complex array of proteins and glycoproteins located on the outermost layers of the C. difficile spore, specifically the spore coat and the exosporium (Pizarro-Guajardo et al., 2016). Key antigens include the Bacillus collagen-like protein A1 (BclA1), which is a major component of the exosporium, and various Cde (Clostridium difficile exosporium) and Cot (spore coat) proteins like CdeC and CdeM (Calderón-Romero et al., 2018). These antigens are critical for the spore's structural integrity, its ability to survive harsh environmental conditions, and the initial stages of host colonization, including adherence to intestinal epithelial cells and the initiation of germination (Paredes-Sabja et al., 2014). Because the spore is the primary transmission vehicle and is highly resistant to standard antibiotics, these surface antigens represent vital therapeutic targets for preventing Clostridioides difficile infection (CDI) and its recurrence (Zhu et al., 2018). Current drug development efforts focus on vaccines and monoclonal antibodies, such as the experimental PA-50 antibody, which aim to neutralize the spore's infectivity by blocking adherence or promoting immune-mediated clearance through opsonophagocytosis (Wang et al., 2018). Targeting these antigens provides a strategy to intercept the pathogen before it can transition into the toxin-producing vegetative state that causes clinical disease.
Inhibition of spore adherence to host intestinal epithelium, neutralization of the germination process, and induction of opsonophagocytosis to facilitate immune-mediated clearance of dormant spores.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridioides difficile spore surface antigens (C. diff spore antigens).